Targeted integration enables predictable clonal cell lines, enhancing transgene control and accelerating biopharma cell line development.
Fei Chen
Advertisement
Fei Chen, PhD, is head, Cell Line Development, at WuXi Biologics.
Articles by Fei Chen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5